Case Study: Landscape and development opportunities assessment in non-muscle invasive bladder cancer (NMIBC)

Project objective

• Our client wanted to understand the non-muscle invasive bladder cancer (NMIBC) disease landscape, specifically for high-risk patients unresponsive to current non-surgical standard of care, for Germany, France, and Canada.

• They wanted to determine the stakeholder assessments of burden and unmet need within NMIBC and perceptions of current treatments.

• Our client was seeking input on payer expectations for clinical trials in the disease area, including trial design, choice of endpoints, and magnitude of expected improvement over standard of care.

Windrose approach

• We conducted robust qualitative interviews with 2 KOLs and 3 payers per country (Germany, France, and Canada).

• 60-min interviews were conducted to understand disease perceptions and test trial designs across different patient classifications.

Impact

• We provided in depth insights from stakeholders on the perceptions of burden and unmet need within NMIBC; as well as current treatment practices across patient populations

• Stakeholder assessments of pipeline agents and expected Health Technology Assessment (HTA) outcomes

• Our insights on evidence expectations for clinical endpoints and which clinical endpoints are most preferred for use in clinical trials; informed the client research and trial design.